Life sciences accounting can go sideways fast. One messy accrual, one sloppy revenue estimate, and suddenly the quarter looks like it took a wrong turn into a lab freezer.
Over 2005–2024, companies with Big R restatements reported an auditor change in the prior year at an average rate of 29%, versus 11% across the broader population.
Reporting errors do not just bruise pride. They burn time, cash, and credibility.
Start With A Risk Map, Not A Spreadsheet
The best close process starts before the month-end. Life sciences teams deal with R&D costs, revenue recognition, income taxes, contingencies, and financial statement disclosures that require heavy judgment.
A smart team or a reliable accounting firm maps its highest-risk accounts first: collaboration revenue, rebates, chargebacks, trial accruals, pre-launch inventory, tax credits, and cash flow classification. Then it assigns an owner, a review step, a source document, and a cutoff rule to each one. That sounds boring, which usually means it works.
Treat Revenue Estimates Like A Controlled Substance
In the life sciences, revenue rarely behaves like a neat little invoice: units sold times price. SEC comment letter guidance notes that revenue in this industry often depends on estimates for returns, chargebacks, rebates, discounts, promotions, shelf-stock adjustments, and similar reductions to transaction price.
That means finance teams need a disciplined estimate process, not optimism with a calculator. Build one schedule that ties gross sales to every deduction bucket, update assumptions each reporting period, and document why each rate changed. If commercial, government, and channel data disagree, stop and reconcile them before the close.
Hope is not a revenue policy.
Do Not Lump Collaboration Deals Into One Accounting Bucket
Life sciences teams love complex partnership agreements almost as much as lawyers do. The problem arrives when finance treats the whole contract as one thing.
Registrants must explain why parts of a collaboration fall outside ASC 606 and why a partner is or is not a customer for a given unit of account. FASB’s collaborative arrangements update also says entities cannot present collaborative transactions together with revenue from contracts with customers unless the unit of account falls within Topic 606.
Translation: break the deal apart before the deal breaks your reporting. Review licenses, R&D services, milestones, reimbursements, and profit shares separately.
Tighten Clinical Trial Accruals
Clinical trial accruals create trouble because vendors bill late, CRO reports arrive in waves, and study progress rarely moves in a perfect straight line.
Companies often estimate accrued trial expenses based on known facts, trial progress, service completion, and discussions with outside providers, then adjust those amounts as actual results differ.
That approach only works if finance, clinical operations, and procurement talk to each other on purpose.
Require a month-end status certification from study owners, compare enrollment and site activity against vendor invoices, and challenge stale estimates. Accruals should reflect evidence, not vibes from the project call.
Decide Early Whether Costs Belong In R&D or Inventory
Few mistakes create bigger cleanup jobs than the wrong call on development versus inventory costs. PwC’s pharmaceutical and life sciences guide flags this issue, including questions about raw materials used in development and costs tied to pre-launch inventory.
The same guide also points to judgment around upfront payments, R&D funding arrangements, and manufacturing validation costs. Do not wait until audit week to debate whether a material purchase supported research, future saleable product, or both.
Write the policy before the transaction volume grows. Then require operations and supply-chain teams to code purchases to the right project and purpose on day one. Retroactive sorting usually ends with pain and a long memo.
Defend Your R&D Tax Credit With Records
The IRS does not award points for enthusiasm.
Its guidance says taxpayers must keep records in usable detail to substantiate research credit claims, and failure to maintain those records can justify disallowance. The IRS also states that identifying employees, their services, and the time they spent may be the most important part of auditing the credit.
It further notes that contract research rules require attention to written agreements, rights to results, and who bears cost if the research fails.
So yes, your tax file needs more than a heroic spreadsheet from three deadlines ago. Tie payroll, time support, contracts, statements of work, and project narratives together before you file.
Build Real Control Reviews, Not Ceremonial Ones
A lot of reporting errors survive because reviews look formal but act casual.
The PCAOB says staff continues to identify many deficiencies in auditor communications with audit committees, including failures to communicate significant deficiencies, material weaknesses, corrected misstatements, and related-party matters.
That message should push management teams to do two things:
- escalate corrected errors instead of quietly celebrating that someone caught them
- document what changed, why it changed, and whether the pattern points to a broader control gap.
One corrected entry may save the quarter. Ten corrected entries in the same area usually mean the process needs surgery. Spreadsheets do not confess. People have to ask sharper questions.
Conclusion
Life sciences teams do not need a prettier checklist. They need sharper judgment, cleaner documentation, tighter controls, and earlier conversations around the accounts that attract trouble.
Revenue estimates, collaboration deals, trial accruals, R&D classification, tax credits, and cash flow presentation all demand respect because each one can turn into an expensive reporting error.
If your close process still runs on memory, email archaeology, and last-minute bravery, that is not a system. That is a plot twist. Fix the process before the process writes your next disclosure.
